Ceftibuten is NOT recommended for enteric fever treatment
Ceftibuten has no established role in the treatment of enteric fever and should not be used. The available evidence does not support its use for this indication, and superior alternatives with proven efficacy are readily available.
Why Ceftibuten Should Not Be Used
The provided evidence contains no data whatsoever supporting ceftibuten's efficacy in enteric fever. While ceftibuten is an oral third-generation cephalosporin with activity against various gram-negative organisms 1, 2, its approved indications are limited to:
- Urinary tract infections
- Otitis media
- Pharyngitis/tonsillitis
- Acute exacerbations of chronic bronchitis
- Uncomplicated gonorrhea 3
Enteric fever is conspicuously absent from this list.
Recommended Treatment Options Instead
First-Line: Azithromycin
For uncomplicated enteric fever in otherwise healthy adults, azithromycin is the preferred oral agent based on WHO recommendations and the most recent high-quality evidence 4:
- Dosing: 20 mg/kg once daily (maximum 1 g) for 7 days
- Evidence: Lower clinical failure rates (OR 0.48) and shorter hospital stays compared to fluoroquinolones 4
- Recent validation: A 2026 trial of 1,831 participants confirmed azithromycin monotherapy as effective, with 5.1% treatment failure rate 5
- Relapse rate: <3% 6
Alternative Oral Option: Cefixime (with important caveats)
Cefixime 400 mg daily can be used but has significant limitations 6:
- Treatment failure rates: 4-37.6% reported 6
- Inferior to fluoroquinolones: When compared directly, cefixime showed increased clinical failure (RR 13.39), microbiological failure (RR 4.07), relapse (RR 4.45), and longer fever clearance time (+1.74 days) 7
- When to consider: Only if azithromycin is unavailable or contraindicated, and resistance patterns permit
Intravenous Option: Ceftriaxone
For patients requiring IV therapy or with severe disease, ceftriaxone is preferred 6, 8:
- Dosing: 2-4 g IV once daily for adults; 50-75 mg/kg/day for children (up to 4 g/day)
- Duration: 14 days to reduce relapse risk 6
- Relapse rate: <8% 6
- Universal susceptibility: All S. typhi and S. paratyphi isolates reported to UK HPA in 2006 were sensitive 6
Clinical Decision Algorithm
Choose based on:
Disease severity:
- Uncomplicated, stable patient → Oral azithromycin
- Unstable, severe, or complicated → IV ceftriaxone 6
Geographic resistance patterns:
Route preference:
- Oral therapy possible → Azithromycin first-line
- IV required → Ceftriaxone
Critical Pitfalls to Avoid
- Do not use ceftibuten - no evidence base for enteric fever
- Do not use fluoroquinolones empirically in patients from Asia without susceptibility data (>70% resistance) 6
- Do not use ciprofloxacin disc testing alone - must also test nalidixic acid sensitivity to confirm true fluoroquinolone susceptibility 6
- Do not add cefixime to azithromycin - a 2026 trial showed no benefit from combination therapy 5
- Do not treat for <14 days - shorter courses increase relapse risk 6
Recent Evidence Clarification
The 2026 ACT-South Asia trial definitively showed that adding cefixime to azithromycin provides no benefit over azithromycin alone (treatment failure 5.1% in both groups), supporting WHO's recommendation for azithromycin monotherapy 5. This has important antimicrobial stewardship implications.